“Abiomed Inc. announced that it received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps to provide treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock.”
“Abiomed Inc. announced it received an expanded U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella 2.5 and Impella CP heart pumps for use during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.”
“Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of bleeding after implantation with a Xience everolimus-eluting coronary stent.”
“Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.”
“Five new angiography systems were launched in 2017 that included improvements to speed workflow and improve both image quality and interventional procedural guidance.”
“Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD).”
“Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of January 2018. This is based on website analytics of the month’s 139,874 pageviews:”
“Here are several considerations for physicians when choosing endovascular stent grafts used to treat aortic aneurysms. Multiple devices are available on the market, each with unique features.”
“LimFlow SA, developer of minimally-invasive technology for the treatment of end-stage critical limb ischemia (CLI), announced the completion of enrollment of the original 10-patient cohort in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System.”
“EmboTrap Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to ARISE II (Analysis of Revascularization in Ischemic Stroke with EmboTrap Device), a new clinical trial presented at the American Stroke Association’s (ASA) International Stroke Conference 2018.”
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!